| Atlanta, GA, October 22, 2004 | |||||||||||||||||
 |
|||||||||||||||||
| Caymus Partners LLC Advises BresaGen Limited on Sale to CBio Limited | |||||||||||||||||
|
|||||||||||||||||
|
About BresaGen BresaGen is an Australian-based company focused on (i) the development and production of protein or peptide pharmaceuticals using E. coli, and (ii) the development of cellular therapies for intractable disease using an embryonic stem cell platform. BresaGen supplies biopharmaceutical active pharmaceutical ingredient (API) products and material for clinical trials. About Caymus Partners With offices in Atlanta and New York, Caymus Partners is a leading middle-market investment banking firm, providing merger and acquisition advisory services, private placements and other financial advisory services. Combined, the firm's senior bankers have more than 65 years of experience and have closed over 250 transactions. More information can be found at www.caymuspartners.com. |
|||||||||||||||||
|
|||||||||||||||||
|
Caymus Partners LLC is pleased to announce that BresaGen Limited ("BresaGen" or the "Company"), a protein and peptide producer, has successfully completed its sale to CBio Limited ("CBio"). Both companies are headquartered in Australia. By combining with CBio, BresaGen will now more effectively pursue its core business of contract protein engineering and peptide development. Caymus Partners served as the exclusive advisor to the Board of Directors of BresaGen in the transaction.3475 Lenox Road, Suite 650
Atlanta, GA 30326
(404) 995-8300
17th Floor
New York, NY 10022
(212) 755-3600
© Caymus Partners LLC
Securities Offered through Caymus Securities LLC, Member FINRA/SIPC
Privacy Policy Business Continuity Plan Important Legal Information
